TY - CHAP A1 - Venice Wing Tung Ho A2 - Hor Yue Tan A3 - Ning Wang A4 - Yibin Feng ED1 - Huan Ren Y1 - 2019-09-25 PY - 2019 T1 - Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies N2 - Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment. BT - Tyrosine Kinases as Druggable Targets in Cancer SP - Ch. 5 UR - https://doi.org/10.5772/intechopen.82513 DO - 10.5772/intechopen.82513 SN - 978-1-78984-809-0 PB - IntechOpen CY - Rijeka Y2 - 2022-01-17 ER -